Haemostasis
A comprehensive analysis of haemostasis from a single whole blood sample
How do you assess your patient's haemostasis state? Do you rely on aPTT, PT, TT, INR, FDP, and similar tests?
- These are plasma tests, so how do you measure the effect of cellular elements?
- These are isolated tests, so how do you integrate potentially contradictory results?
- These have static end points (e.g., fibrin formation) - when only 5% of thrombin has been generated, so how do you assess the effect of reactions that take place later in the process?
- These tests measure bleeding, so how to you measure a prothrombotic state?
Monitoring haemostasis using the cell-based model requires a whole blood test to measure the net effect of the interactions among platelets, coagulation factors, and other cellular elements. The TEGŪ 5000 haemostasis System, with a drop of whole blood, draws a picture of the delicate haemostasis balance or imbalance present - depicting all phases of haemostasis from initial fibrin formation through clot lysis. It quantifies hemorrhagic, thrombotic, and fibrinolytic states so you can stratify risk of bleeding and ischemic events and personalize therapies.
What exactly does the TEGŪ 5000 haemostasis System provide?
- A single instrument that provides a total view of your patient's haemostasis: measurements of clotting time, clot formation kinetics, clot strength, and clot lysis from a single 360μl whole blood sample -including assessment of the effects of antiplatelet drugs
- A single system that can be used both point of care as well as in a centralized clinical laboratory
- Real-time haemostasis data and trend analysis that can be viewed anywhere in the hospital, or even outside the hospital
- The only system that reflects the cell-based haemostasis model
What does this mean for your institution?
Availability of individual parameters as well as the net result of all the interactions of all the components of patient whole blood haemostasis, resulting in:
- Ability to stratify risk of bleeding and ischemic events
- Reduced use of blood products and pharmaceuticals and their attendant complications
- Reduced re-exploration
- Reduced costs
- Improved clinical outcomes
This results in better patient care - accurate diagnosis, optimal therapy, and improved clinical outcomes...
Can you afford to make haemostasis decisions without it?
Better, more informed decisions about blood product administration
Blood transfusions can be lifesaving when administered properly - proper product, proper dose, and proper time. They can also be deadly. A recent study by Rao et al1 of over 24,000 ACS patients from the GUSTOIIb, PURSUIT, and PARAGON8 trials shows that a blood transfusion can double the risk of death and triple the risk for another heart attack within a month. Spiess et al2 associated platelet transfusion during CABG with increased risk for serious adverse effects, showing a threefold increase in stroke tendency and fivefold increase in death tendency.
A related problem with blood transfusions is the availability of blood product itself. Each holiday period, appeals to donors are issued to avert critical blood shortages. Many blood bank centers are able to provide only one or two days worth of blood supplies during peak usage periods. As diseases such as hepatitis and HIV continue to spread, blood sources continue to dwindle. These issues, along with others related to blood product usage such as complications and length of hospital stay due to exposure to unneeded transfusions, can be mitigated through better, more informed decisions about blood product administration.
